Dr. Sekar Kathiresan, a member of the Broad Institute of MIT and Harvard, speaks with NPR’s Richard Harris about his work on an experimental genetic scan that could identify people who are likely to become severely overweight. “This work hopefully will destigmatize obesity and make it very similar to every other disease, which is a combination of both lifestyle and genetics,” said Kathiresan.
TIME reporter Alice Park writes that in a Nature commentary, an international group of scientists has called for a temporary ban on studies using gene-editing on human embryos. “Our question is, how should nations make decisions about technologies like gene editing going forward?” says Prof. Eric Lander, director of the Broad Institute and one of the authors of the commentary.
Associated Press reporter Malcom Ritter writes that an international team of scientists – including a number of MIT researchers – has called for a moratorium on making babies with genetically engineered DNA. “The moratorium would allow time for discussion of technical, scientific, societal and ethical issues that must be considered,” explains Ritter.
Financial Times reporter Hannah Kuchler writes that researchers from MIT and a number of other institutions have called for a moratorium on editing inheritable human genes. Kuchler writes that the researchers called for the establishment of “an international framework on the conditions in which such editing could be allowed.”
Prof. Aviv Regev speaks with the Associated Press about the Human Cell Atlas Consortium, which is aimed at cataloging all the cells in the human body in an effort to better understand human diseases. "This is not going to cure all disease immediately," she says, but "it is a critical stepping stone."
MIT researchers developed a new technique to make a more effective and precise CRISPR gene editing system, reports Eileen Drage O’Reilly for Axios. The system uses the new enzyme Cas12b, which has a “small size and precise targeting [that] will enable it to be used for in vivo applications in primary human cells,” O’Reilly explains.
Prof. Aviv Regev speaks with NPR’s Nell Greenfieldboyce about her work with the Human Cell Atlas trying to catalogue every cell in the human body. “We don't need to analyze every individual cell out of 37 trillion because the cells kind of repeat themselves,” says Regev. “All we need to do is sample enough of them from enough region in order to get comprehensive coverage.”
Writing for The Boston Globe, Prof. Eric Lander, president of the Broad Institute, argues for enabling cancer patients to become actively involved in cancer research. “Patients must have an active voice in decisions. Patient data should never be sold,” Lander writes. “Researchers anywhere should have rapid access to the de-identified clinical and genomic data, to ensure that anyone can make discoveries.”
Wired reporter Megan Molteni highlights Prof. Aviv Regev’s work leading the Human Cell Atlas, an effort to catalog the cells in the human body that could eventually serve as a roadmap for understanding and treating disease. “From the beginning we have designed this as a public good and an open resource to enable science around the world,” Regev explains.
Prof. Aviv Regev speaks with WBUR’s Karen Weintraub about her work exploring human cells. Regev says she was inspired to study the human cell as, “it’s this phenomenal entity that knows how to take many different pieces of information, make very quick and sophisticated decisions, act on them and continue on its way.”
STAT reporter Justin Chen writes about a new study that examines why patients with pancreatic cancer often experience significant weight loss. Prof. Matt Vander Heiden explains that the findings show, “pancreatic cancer patients clearly have a lot of tissue wasting and whether it’s good or bad, we can now say that it’s not necessarily bad at diagnosis.”
Professors Edward Boyden and Feng Zhang have been named to the 2018 class of Howard Hughes Medical Institute investigators, reports Jonathan Saltzman for The Boston Globe. “We selected these scientists because they know how to ask hard and interesting questions with skill and intellectual courage,” says David Clapham, vice president and chief scientific officer of the institute.
The Broad Institute of MIT and Harvard is developing a Drug Repurposing Hub, which looks to “acquire samples of every drug ever developed to see if they can be used to treat diseases besides those for which they were intended,” writes Jonathan Saltzman for The Boston Globe.
Researchers at the Broad Institute of MIT and Harvard have programmed CRISPR to “in essence, make edits when significant cellular events occur,” writes Kristin Brown for Gizmodo. “All this adds up to the potential of CRISPR as not just a gene-editing powerhouse, but a multifunctional tool that also works as a biosensor, a medical detective, and an invaluable instrument for basic research.”
A gene-editing tool called SHERLOCK, developed in Prof. Feng Zhang’s lab, allows for faster detection of infections and viruses, such as Zika and Dengue fever. “It does this by combining different types of CRISPR enzymes, which are unleashed together to target distinct bits of DNA and RNA, another of the major biological molecules found in all forms of life,” writes Alessandra Potenza for The Verge.